Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

Phase 2 Completed 30 enrolled Arog Pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a single-arm, Phase II study of crenolanib as maintenance in AML patients with FLT3 mutations who have achieved complete remission (CR) after allogeneic stem cell transplantation. Oral crenolanib will be administered daily post-transplant for up to two years.

Timeline

Start: 2015-09
Primary completion: 2022-05
Completion: 2022-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Crenolanib	Small molecule	100 mg	Oral

Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

Summary

Timeline

Drugs

Indications